Q-omics provides the consensus-scored PAPOLB profile across patient tissues and cancer cell-line models. PAPOLB expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PAPOLB is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, PAPOLB RNA expression shows 13,895 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where PAPOLB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAPOLB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAPOLB survival associations across molecular data types. PAPOLB RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAPOLB RNA expression–survival associations across cancer types. High PAPOLB expression shows unfavorable associations in ACC, KICH, LIHC, DLBC and THCA, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for PAPOLB RNA expression.
This table summarizes PAPOLB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PAPOLB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAPOLB shows lower tumor expression in THCA, KICH, KIRC, BRCA, KIRP and LUAD. The THCA box plot shows higher PAPOLB RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p < 0.001).
This table shows molecular features associated with PAPOLB in patient tissues and cancer cell lines. In patient samples, PAPOLB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAPOLB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and OESOPHAGUS.
